Published 6 hours ago • loading... • Updated 6 hours ago

Novo Nordisk Deal Puts Focus On Next Generation Of Oral GLP-1 Treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral GLP-1 treatment for obesity and type 2 diabetes.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

DirectorsTalk Interviews

Novo Nordisk Deal Puts Focus On Next Generation Of Oral GLP-1 Treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral GLP-1 treatment for obesity and type 2 diabetes.

6 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated4 hours agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

DirectorsTalk Interviews broke the news 6 hours ago on Thursday, November 12, 2026.

Sources are mostly out of (0)

Novo Nordisk Deal Puts Focus On Next Generation Of Oral GLP-1 Treatments

1 Articles

1 Articles

Novo Nordisk Deal Puts Focus On Next Generation Of Oral GLP-1 Treatments

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China

They Warn About Possible Loss of Vision by Using Weight-Loss Medicines

Anvisa Determines the Collection of Inputs Used in Slimming Pens

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Health. Anti-Obesity Medicines: Almost One in Five Frenchmen Would Be Tempted, Even without Being Obese

Korea Warns of Rare Vision-Loss Risk Linked to GLP-1 Drugs

Similar News Topics

Similar News Topics

More stories like this

Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China

They Warn About Possible Loss of Vision by Using Weight-Loss Medicines

Anvisa Determines the Collection of Inputs Used in Slimming Pens

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Health. Anti-Obesity Medicines: Almost One in Five Frenchmen Would Be Tempted, Even without Being Obese

Korea Warns of Rare Vision-Loss Risk Linked to GLP-1 Drugs

Novo Nordisk Deal Puts Focus On Next Generation Of Oral GLP-1 Treatments

1 Articles

1 Articles

Novo Nordisk Deal Puts Focus On Next Generation Of Oral GLP-1 Treatments

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China

They Warn About Possible Loss of Vision by Using Weight-Loss Medicines

Anvisa Determines the Collection of Inputs Used in Slimming Pens

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Health. Anti-Obesity Medicines: Almost One in Five Frenchmen Would Be Tempted, Even without Being Obese

Korea Warns of Rare Vision-Loss Risk Linked to GLP-1 Drugs

Similar News Topics

Similar News Topics

More stories like this

Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China

They Warn About Possible Loss of Vision by Using Weight-Loss Medicines

Anvisa Determines the Collection of Inputs Used in Slimming Pens

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Health. Anti-Obesity Medicines: Almost One in Five Frenchmen Would Be Tempted, Even without Being Obese

Korea Warns of Rare Vision-Loss Risk Linked to GLP-1 Drugs

Bias Distribution

Factuality